The global biobanking market size was valued at USD 59.98 billion in 2025 and is projected to grow from USD 64.37 billion in 2026 to USD 113.27 billion by 2034, registering a CAGR of 7.32% during the forecast period from 2026 to 2034. Europe dominated the biobanking market with a market share of 36.4% in 2025.
Biobanking refers to the collection, processing, storage, and management of biological samples such as blood, tissues, DNA, and cells for research, clinical, and therapeutic applications. These repositories play a vital role in advancing precision medicine, drug discovery, regenerative medicine, and disease research by providing high-quality biological specimens and associated data.
The biobanking market demand is increasing due to the growing focus on personalized medicine, genomic research, and the rising prevalence of chronic diseases. Expanding clinical trials, increasing investments in life sciences research, and advancements in sample preservation technologies are supporting market growth. Additionally, the growing adoption of digital biobanking solutions and collaborative research initiatives is further driving industry expansion.
Download a Free Sample To learn more about this report,
Adoption of Cloud-Based Biobank Data Platforms
The growing volume of genomic, clinical, imaging, and biomarker data is increasing the need for scalable and secure data management in biobanks. Cloud-based platforms allow researchers to access and analyze large datasets without maintaining extensive local computing infrastructure, as demonstrated by the UK Biobank Research Analysis Platform, which supports access to more than 30 petabytes of centrally stored data. This transition can improve data accessibility, computational flexibility, and collaboration across research teams.
Integration of Multi-Omics Data With Biobank Samples
The growing need to understand diseases through multiple biological layers is encouraging biobanks to connect genomic, proteomic, biomarker, imaging, and clinical information with stored samples. The UK Biobank, for example, provides whole-genome and exome sequencing for 500,000 participants alongside proteomics data for 54,000 participants, creating opportunities to analyze different data types together. This integration can support more comprehensive biomarker discovery, disease research, and development of precision medicine approaches.
Large-Scale Sample Collections and Drug Discovery Drive Market
The need for large and diverse human sample collections creates demand for biobanks that can provide well-characterized biological materials for population and disease research. The U.K. Biobank has collected biological samples and health information from around 500,000 participants, demonstrating the scale of collections used for biomedical research. For example, blood, urine, saliva, and DNA samples can be linked with health and lifestyle information to support studies across different diseases and population groups. This research requirement supports investment in sample collection, processing, storage, and quality-control infrastructure.
The use of human biological samples in drug discovery creates demand for biobanks that can supply researchers with clinically relevant specimens. NIH's National Cancer Institute maintains biorepositories that provide biospecimens for cancer research, including tissue, blood, and other biological materials used to investigate disease mechanisms and potential therapeutic targets. For example, tumor tissue samples can support biomarker studies and evaluation of potential cancer therapies during drug-development research. This application supports the supply of well-characterized specimens and encourages biobanks to maintain collections suitable for pharmaceutical and biotechnology research.
Sample Quality and Data Privacy Challenges Restrain Market Expansion
Sample quality and standardization challenges can arise from differences in collection, processing, storage, and transportation procedures across biobanking facilities. The International Society for Biological and Environmental Repositories highlights standardized collection, processing, storage, and quality-management practices as important for maintaining biospecimen quality and reproducibility. These variations can affect specimen integrity, reduce research confidence, and slow the adoption of biobanking services.
Data privacy and security concerns can arise because biobanks link biological samples with sensitive genetic, clinical, and personal information. The National Human Genome Research Institute notes that genomic data can raise privacy concerns because genetic information may reveal sensitive information about individuals and their relatives. These concerns can increase governance requirements, reduce donor willingness to participate, and limit the expansion of biobanking activities.
Specialized Disease Biobanks and Quality-Certified Operations Offers Growth Opportunities
Pharmaceutical companies, diagnostic developers, and research institutions can use disease-specific biobanks for targeted studies and biomarker research. Coriell Institute provides samples representing cancer, infectious, respiratory, and cardiology diseases and offers tailored sample procurement, creating revenue through customized biospecimen services.
Biobank operators, research institutions, and sample-storage providers can adopt standardized quality systems to strengthen trust among pharmaceutical and academic customers. ISO 20387 specifies quality-control and competency requirements for biobanks, supporting higher-value sample services and research collaborations where documented sample quality is important.
Funding Constraints and Ethical Governance Hinders Growth
Biobanks require long-term funding for sample acquisition, preservation, storage, staffing, and facility maintenance. Startup costs can require millions of dollars, while many biobanks depend on short-term grants, institutional sponsorship, philanthropy, or project-based funding for ongoing operations. These funding constraints can limit capacity expansion and discourage investment in new biobanking infrastructure.
Biobanks must manage consent for future research uses, sample withdrawal, commercialization, and changing research applications over long periods. In a large U.S. survey of 13,000 respondents, 66% reported willingness to participate in biobank research, while 86% wanted to know what would happen if researchers misused their health information, highlighting the importance of clear governance and communication. These requirements can increase administrative workloads, complicate donor recruitment, and slow expansion of large-scale collections.
The product segment accounted for a share of 61.8% in 2025, owing to the widespread use of biobanking equipment, storage systems, consumables, and other products required for sample collection, processing, preservation, and storage. the increasing demand for high-quality biological sample management and growing biobanking activities further strengthen the segment’s dominant position in the biobanking market.
The services segment is expected to grow at a CAGR of 8.41% during the forecast period, driven by increasing demand for sample management, storage, processing, data management, and specialized biobanking services. the growing complexity of biological sample handling and rising adoption of outsourced biobanking services further support the segment’s growth.
Request Customizationto receive a tailored report.
The human tissues segment accounted for a share of 36.7% in 2025, supported by the widespread use of human tissue samples in biomedical research, drug development, disease studies, and personalized medicine. the increasing demand for high-quality human biospecimens and growing biobanking activities further strengthen the segment’s dominant position in the biobanking market.
The stem cells segment is expected to grow at a CAGR of 8.74% during the forecast period, propelled by increasing applications of stem cells in regenerative medicine, drug discovery, disease modeling, and cell-based research. the human organs segment supports research and transplantation-related applications, while the other biospecimens segment includes blood, plasma, genetic materials, and other biological samples used across research and clinical applications.
The tissue biobanks segment accounted for a share of 34.8% in 2025, supported by the widespread collection and storage of human tissue samples for biomedical research, drug development, disease studies, and personalized medicine. the growing demand for high-quality tissue specimens and increasing research activities further strengthen the segment’s dominant position in the biobanking market.
The genetic (DNA/RNA) segment is expected to grow at a CAGR of 8.19% during the forecast period, propelled by increasing demand for genetic research, molecular diagnostics, precision medicine, and genomic studies. the population-based biobanks segment supports large-scale research using samples and health data from diverse populations, while the disease-based biobanks segment contributes through the collection of specimens associated with specific diseases and conditions.
Speak to an Analystto discuss market opportunities.
The Europe biobanking market accounted for the largest regional share of 36.4% in 2025, supported by established biobanking infrastructure, strong biomedical research activity, and increasing demand for high-quality biological samples. In the U.K. biobanking market, UK Biobank is expanding its infrastructure in 2026, with more than 11 million biological samples being moved to a new Manchester facility equipped with four automated freezers capable of holding up to 20 million samples. The new facility is expected to increase sample-retrieval capacity to around 1 million samples annually, supporting expanded biomedical research and biobanking activities.
In the Germany biobanking market, the nationwide Biobank Platform for Germany began implementation in July 2026 with funding from the Federal Ministry of Research, Technology and Space. The platform is designed to improve access to biological samples such as blood and tissue, together with associated clinical and analytical data, for medical research while maintaining quality, data-protection, and ethical standards. Meanwhile, the France biobanking market is supported by Inserm's France BioBank Network, which launched its newsletter in May 2026 to support the structuring and valorization of biological collections for research and development. In addition, the BioCF national infrastructure is consolidating biological samples from five major French population cohorts, representing nearly 400,000 volunteers, with more than 130,000 participants having already provided biological samples such as blood, urine, and saliva.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific biobanking market is expected to grow at a CAGR of 9.35%, showcasing the fastest-growing regional market, driven by expanding research capabilities, increasing healthcare investments, and rising demand for biological sample storage and analysis. In Japan, the Japan biobanking market is supported by the Japan agency for medical research and development’s B-cure next program launched in fiscal 2026, which supports population and disease biobanks and integrates genomic, omics, and clinical data for drug discovery and diagnostics.
In China biobanking market is supported by advances in biobank standardization, with the national standard GB/T 47332-2026 on sharing human biomaterials and related data issued in march 2026 and effective from july 2026, establishing a framework for biobank sample and data sharing. In South Korea biobanking market is supported by the national biobank of korea, which acquires samples from approximately 40,000 individuals annually and maintained samples from 466,303 individuals as of december 2024, strengthening the country’s biological sample infrastructure for biomedical research. In India biobanking market is supported by the indian council of medical research, which issued 2026 guidelines for establishing biorepositories in its institutes and promoted the use of samples from the ICMR-INDIAB study biobank, supporting broader utilization of stored biological samples for biomedical research.
The North America biobanking market accounted for a regional share of 31.8% in 2025, supported by advanced research infrastructure, strong pharmaceutical and biotechnology activity, and increasing use of biospecimens in biomedical research. The U.S. biobanking market is supported by large-scale collection and storage of human biospecimens for biomedical research. The NIH all of Us research program reports more than 334,000 participants who have donated biospecimens, with 2.3 million primary tubes processed and 9.0 million secondary aliquots stored, supporting research in genomics, disease biology, and precision medicine.
The Canada biobanking market is supported by government-backed biobank infrastructure and investment in biological specimen resources. Innovation, science and economic development Canada awarded the ottawa hospital research institute C$1.25 million in 2025 to maintain and upgrade a Canadian biobank data platform connecting academia, government, and industry and enabling coordinated access to biological specimens and data for research and preparedness.
The Middle East and Africa biobanking market is expected to grow at a CAGR of 6.41%, driven by improving healthcare infrastructure, expanding biomedical research initiatives, and growing adoption of organized biological sample repositories. The UAE biobanking market is expected to benefit from the country’s expanding genomics, precision medicine, and biomedical research infrastructure. In April 2026, the department of health – abu dhabi inaugurated the abu dhabi biobank, a state-of-the-art facility in masdar city with capacity to store more than 100,000 cord blood samples and up to five million biological samples. The biobank links biological samples with genomic, lifestyle, and clinical data to support earlier disease detection, personalized care, and population-level research, strengthening demand for advanced biobanking infrastructure and services.
The Africa biobanking market is expected to benefit from continued development of continental biobanking and genomic research infrastructure. Africa CDC’s network information management system now includes dedicated biobanking and diagnostics modules for managing biospecimen collection, storage, retrieval, shipment, and quality assurance across the African union laboratory network. In 2026, Africa CDC also emphasized the importance of biobanking for collecting and storing well-characterized specimens to support diagnostic development and evaluation, while its 2025 annual report noted that the continental biobanking network covers all regions of Africa.
The biobanking market is moderately fragmented, with biobanks, academic and research institutions, biotechnology companies, pharmaceutical companies, healthcare organizations, contract research organizations, specimen management providers, and specialized biobanking technology companies competing across biological sample collection, storage, processing, management, and research applications. Established players compete primarily on sample quality, storage capacity, biospecimen diversity, data management capabilities, automation, preservation technologies, regulatory compliance, quality standards, research and development, security, and global collaboration networks, with leading players such as thermo fisher scientific, azenta life sciences, bd, merck kgaa, and avantor estimated to account for approximately 45% of the global market based on their product portfolios, biobanking capabilities, geographic presence, and competitive positioning.
Emerging and regional players within the biobanking market ecosystem compete through cost-effective biobanking services, specialized specimen collections, advanced storage technologies, flexible sample management solutions, digital platforms, localized services, customized workflows, and application-specific offerings to address evolving research requirements and strengthen their market presence. these players also focus on developing specialized specimen management solutions, improving storage efficiency, and expanding digital biobanking capabilities to differentiate their offerings and broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Red Biotechnology Market Size, Share, Growth, Forecast, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Cell Line Development Services Market Size, Share, 2034
Base Editing Market Size, Share, Growth, Analysis, Report, 2034
Metagenomic Sequencing Market Size, Share, Growth, Analysis, 2034
Gene Therapy Cell Culture Media Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com